{
  "actions": [
    {
      "acted_at": "2007-02-16",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2007-02-16",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Energy and Commerce.",
      "type": "referral"
    },
    {
      "acted_at": "2007-02-17",
      "action_code": "B00100",
      "references": [
        {
          "reference": "CR E390-391",
          "type": null
        }
      ],
      "text": "Sponsor introductory remarks on measure.",
      "type": "action"
    },
    {
      "acted_at": "2007-02-27",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr1165-110",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "14"
    }
  ],
  "congress": "110",
  "cosponsors": [
    {
      "bioguide_id": "E000215",
      "district": "14",
      "name": "Eshoo, Anna G.",
      "original_cosponsor": false,
      "sponsored_at": "2007-05-09",
      "state": "CA",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2007-02-16",
  "number": "1165",
  "official_title": "To amend the Federal Food, Drug, and Cosmetic Act to establish additional authorities to ensure the safe and effective use of drugs, to establish whistleblower protections for certain individuals, and for other purposes.",
  "popular_title": null,
  "related_bills": [],
  "short_title": "SAFE Drug Act",
  "sponsor": {
    "bioguide_id": "M000133",
    "district": "7",
    "name": "Markey, Edward J.",
    "state": "MA",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2007-02-16",
  "subjects": [
    "Administrative remedies",
    "Censorship",
    "Civil Rights and Liberties, Minority Issues",
    "Civil actions and liability",
    "Commerce",
    "Communication in medicine",
    "Communication in science",
    "Congressional reporting requirements",
    "Crime and Law Enforcement",
    "Criminal justice information",
    "Damages",
    "Deceptive advertising",
    "Department of Health and Human Services",
    "Department of Labor",
    "Disciplining of employees",
    "Discrimination in employment",
    "Dismissal of employees",
    "Drug approvals",
    "Drug industry",
    "Drugs",
    "Economics and Public Finance",
    "Federal advisory bodies",
    "Federal employees",
    "Federal officials",
    "Fines (Penalties)",
    "Food and Drug Administration (FDA)",
    "Fraud",
    "Government Operations and Politics",
    "Government contractors",
    "Government publicity",
    "Health",
    "Informed consent (Medical law)",
    "Labeling",
    "Labor and Employment",
    "Law",
    "Legal fees",
    "Marketing",
    "Misconduct in office",
    "Pharmaceutical research",
    "Punitive damages",
    "Risk",
    "Science, Technology, Communications",
    "Scientists in government",
    "Subcontractors",
    "Wage restitution",
    "Waste in government spending",
    "Whistle blowing"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2007-02-16",
    "date": "2007-05-04T20:17:07Z",
    "text": "Swift Approval, Full Evaluation Drug Act or the SAFE Drug Act - Amends the Federal Food, Drug, and Cosmetic Act to authorize the Secretary of Health and Human Services to: (1) order postmarket studies of approved drugs upon receiving evidence of a significant issue regarding the safety or lack of effectiveness of such a drug; and (2) establish restrictions on the distribution or use of the drug during the period in which the study is conducted.\n\nDirects the Secretary to amend regulations to require postmarket studies of drugs approved under an accelerated approval process for new drugs for serious or life-threatening illnesses.\n\nDeems a drug or device to be misbranded if there is a failure to comply with requirements under this Act.\n\nProhibits discrimination against individuals who provide information in an investigation or proceeding regarding a violation of any law, rule, or regulation, censorship, distortion, or suppression of scientific information, research, or analysis, or the willful disclosure of false, misleading, or incomplete scientific information.\n\nAuthorizes Food and Drug Administration (FDA) officers, employees, and sponsored individuals to publish in peer-reviewed journals and other scientific publications and make oral presentations at professional society meetings and other meetings of their peers, with certain exceptions.\n\nProhibits an FDA officer or employee from directing any other FDA officer or employee to: (1) censor, distort, or suppress any scientific research, analysis, opinion, or recommendation; or (2) willfully disclose scientific information that is false, misleading, or incomplete.\n\nRequires the Secretary to publish a summary statement of the scientific basis for approval of any new drug and how the final decision balanced the risk and benefits within 48 hours after approval of an application."
  },
  "titles": [
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend the Federal Food, Drug, and Cosmetic Act to establish additional authorities to ensure the safe and effective use of drugs, to establish whistleblower protections for certain individuals, and for other purposes.",
      "type": "official"
    },
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Swift Approval, Full Evaluation Drug Act",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "SAFE Drug Act",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Swift Approval, Full Evaluation Drug Act",
      "type": "short"
    }
  ],
  "updated_at": "2023-01-11T20:02:13Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/110/hr/BILLSTATUS-110hr1165.xml"
}